The pharmacological and physicochemical characteristics of Bicycles also make them well-suited for ophthalmology indications. Bicycle has partnered with leading ophthalmology company Oxurion, formerly ThromboGenics, for the development of novel plasma kallikrein inhibitors, including THR-149 for the treatment of diabetic macular edema (DME). A Phase 1 clinical study of THR-149 in patients with DME was completed in July 2019 and positive topline results were announced, showing that THR-149 was well-tolerated and safe, with improvements to patients’ best corrected visual acuity (BCVA) starting at Day 1 and maintained out to Day 90. More on the Phase 1 results can be read here. Bicycle receives milestones and royalty payments from the collaboration. Bicycle and Oxurion extended the alliance in January 2018.